The split views on the Institute for Clinical and Economic Review (ICER) were on display during a panel discussion at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) recent meeting in New Orleans, according to a report on the American Journal of Managed Care.
National Pharmaceutical Council (NPC) CSO and Executive Vice President Robert Dubois said during the panel that ICER represents a strain on choice, while Harvard Pilgrim Health Care’s Michael Sherman and University of Sheffield’s Ron Akehurst provided a different perspective.
“I do believe that ICER is informing decisions,” Sherman said.
To read the full report on AJMC, click here.
